Dipòsit Digital de Documents de la UAB 9 registres trobats  La cerca s'ha fet en 0.01 segons. 
1.
17 p, 1.4 MB Mephedrone and Alcohol Interactions in Humans / Papaseit Fontanet, Esther (Department of Pharmacology, Therapeutics and Toxicology and Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona (UAB)) ; Pérez Mañá, Clara (Department of Pharmacology, Therapeutics and Toxicology and Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona (UAB)) ; de Sousa Fernandes Perna, Elizabeth B. (Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University) ; Olesti, Eulalia (Department of Health and Life Sciences, Universitat Pompeu Fabra (CEXS-UPF)) ; Mateus, Julian (Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM-Hospital del Mar Medical Research Institute, Parc de Salut Mar) ; Kuypers, Kim PC (Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University) ; Theunissen, Eef L. (Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University) ; Fonseca Casals, Francina, 1972- (Institut de Neuropsiquiatria i Adiccions, Addiction Unit and IMIM) ; Torrens, Marta (Institut de Neuropsiquiatria i Adiccions, Addiction Unit and IMIM) ; Ramaekers, Jan G. (Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University) ; de la Torre, Rafael (CIBER de Fisiopatología de la Obesidad y Nutrición (CB06/03), CIBEROBN) ; Farré Albaladejo, Magí (Department of Pharmacology, Therapeutics and Toxicology and Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona (UAB))
Mephedrone (4-MMC, mephedrone) is a synthetic cathinone derivative included in the class of new psychoactive substances. It is commonly used simultaneously with alcohol (ethanol). The aim of the present study was to evaluate the interactions on subjective, cardiovascular and hormone effects and pharmacokinetics between mephedrone and alcohol in humans. [...]
2020 - 10.3389/fphar.2019.01588
Frontiers in Pharmacology, Vol. 10 (january 2020)  
2.
9 p, 602.7 KB MDMA-Induced Dissociative State not Mediated by the 5-HT2A Receptor / Puxty, Drew J. (Maastricht University. Department of Neuropsychology and Psychopharmacology) ; Ramaekers, Johannes G. (Maastricht University. Department of Neuropsychology and Psychopharmacology) ; de la Torre, Rafael (Institut Hospital del Mar d'Investigacions Mèdiques) ; Farré, Magí (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pizarro, Neus (Universitat Autonoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Pujadas, Mitona (Institut Hospital del Mar d'Investigacions Mèdiques) ; Kuypers, Kim P. C. (Maastricht University. Department of Neuropsychology and Psychopharmacology)
Previous research has shown that a single dose of MDMA induce a dissociative state, by elevating feelings of depersonalization and derealization. Typically, it is assumed that action on the 5-HT2A receptor is the mechanism underlying these psychedelic experiences. [...]
2017 - 10.3389/fphar.2017.00455
Frontiers in Pharmacology, Vol. 8 Núm. 455 (july 2017)  
3. / Baeta-Corral, Raquel (Universitat Autònoma de Barcelona. Institut de Neurociències The work received support by Instituto de Salud Carlos III, ISC3 PI10/00283 Spain, UAB GE260804. BJ received support by the Åhlén Foundation and the Stockholm County Council (ALF 20170190). RB-C received a predoctoral grant FI-DGR (2012FI_B1 00198) from Secretaria d'Universitats i Recerca, Departament d'Economia i Coneixement, Generalitat de Catalunya. We thank Ismael Álvarez-Montón for his assistance in the chronic caffeine treatment. The animals used in the present study came from the colony of homozygous 3xTgAD and wild-type NTg mice established by Dr. LG-L at the Universitat Autònoma de Barcelona, Spain, from progenitors kindly provided by Prof. Frank M. LaFerla, Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA, United States.) ; Johansson, Björn (Department of Geriatrics, Karolinska University Hospital) ; Giménez-Llort, Lydia (Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona)
Coffee or caffeine has recently been suggested as prophylaxis for dementia. Although memory problems are hallmarks of Alzheimer's disease, this dementia is also characterized by neuropsychiatric symptoms called Behavioral and Psychological Symptoms of Dementia (BPSD). [...]
2018 - 10.3389/fphar.2018.00079
Frontiers in Pharmacology, Vol. 9 (february 2018)  
17 p, 4.1 MB
4.
13 p, 1.0 MB Adaptive Pathways : Possible Next Steps for Payers in Preparation for Their Potential Implementation / Vella Bonanno, Patricia (Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde) ; Ermisch, Michael (Pharmaceutical Department, National Association of Statutory Health Insurance Funds) ; Godman, Brian (Division of Clinical Pharmacology, Karolinska Institutet) ; Martin, Antony P. (Health Economics Centre, University of Liverpool Management School) ; Van Den Bergh, Jesper (Department of Health) ; Bezmelnitsyna, Liudmila (National Research Institution for Public Health) ; Bucsics, Anna (Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA)) ; Arickx, Francis (Department of Pharmaceutical Policy, National Institute for Health and Disability Insurance) ; Bybau, Alexander (Zilveren Kruis Achmea) ; Bochenek, Tomasz (Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College) ; van de Casteele, Marc (Department of Pharmaceutical Policy, National Institute for Health and Disability Insurance) ; Diogene, Eduardo (Hospital Universitari Vall d'Hebron) ; Eriksson, Irene (Department of Medicine Solna, Karolinska Institutet) ; Fürst, Jurij (Medicinal Products Department, Health Insurance Institute of Slovenia) ; Gad, Mohamed (Global Health and Development Group, Imperial College) ; Greičiūtė-Kuprijanov, Ieva (Department of Pharmacy, Ministry of Health of the Republic of Lithuania) ; van der Graaff, Martin (National Health Care Institute (ZIN)) ; Gulbinovic, Jolanta (State Medicines Control Agency) ; Jones, Jan (Scottish Medicines Consortium) ; Joppi, Roberta (Clinical Research and Drug Assessment Unit) ; Kalaba, Marija (Pediatric Cardiology, Primary Healthcare Centre "Zemun") ; Laius, Ott (Department of Post-authorisation Safety, State Agency of Medicines) ; Langner, Irene (Wissenschaftliches Institut der AOK) ; Mardare, Ileana (Faculty of Medicine, Public Health and Management Department, "Carol Davila" University of Medicine and Pharmacy Bucharest) ; Markovic-Pekovic, Vanda (Department of Social Pharmacy, Medical Faculty, University of Banja Luka) ; Magnusson, Einar (Department of Health Services, Ministry of Health) ; Melien, Oyvind (Norwegian Directorate for Health) ; Meshkov, Dmitry O. (Department of Health) ; Petrova, Guenka I. (Department of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical University of Sofia) ; Selke, Gisbert (Wissenschaftliches Institut der AOK) ; Sermet, Catherine (Institut de Recherche et Documentation en Economie de la Santé (IRDES)) ; Simoens, Steven (KU Leuven Department of Pharmaceutical and Pharmacological Sciences) ; Schuurman, Ad (National Health Care Institute (ZIN)) ; Ramos, Ricardo (Health Technology Assessment, Pricing and Reimbursement Department, Central Administration of the Health System, National Authority of Medicines and Health Products (I.P., INFARMED)) ; Rodrigues, Jorge (Health Technology Assessment, Pricing and Reimbursement Department, Central Administration of the Health System, National Authority of Medicines and Health Products (I.P., INFARMED)) ; Zara, Corinne (Barcelona Health Region, Catalan Health Service) ; Zebedin-Brandl, Eva (Department of Pharmaceutical Affairs, Main Association of Austrian Social Insurance Institutions) ; Haycox, Alan (Health Economics Centre, University of Liverpool Management School) ; Universitat Autònoma de Barcelona
Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The "introduction" of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not consulted or involved. [...]
2017 - 10.3389/fphar.2017.00497
Frontiers in Pharmacology, Vol. 8 (august 2017)  
5.
11 p, 1.1 MB Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs / Godman, Brian (University of Strathclyde) ; Malmström, Rickard E. (Karolinska University Hospital Solna) ; Diogene, Eduardo (Hospital Universitari Vall d'Hebron) ; Jayathissa, Sisira (Hutt Valley DHB. Department of Medicine,) ; McTaggart, Stuart (NHS National Services Scotland) ; Cars, Thomas (Uppsala University. Department of Medical Sciences,) ; Alvarez-Madrazo, Samantha (University of Strathclyde) ; Baumgärtel, Christoph (Austrian Medicines and Medical Devices Agency) ; Brzezinska, Anna (Agency for Health Technology Assessment) ; Bucsics, Anna (Hauptverband der Österreichischen Sozialversicherungsträger) ; Campbell, Stephen (University of Manchester. Centre for Primary Care) ; Eriksson, Irene (Stockholm County Council. Department of Healthcare Development,) ; Finlayson, Alexander (University of Oxford. Green Templeton College,) ; Fürst, Jurij (Health Insurance Institute) ; Garuoliene, Kristina (National Health Insurance Fund) ; Gutiérrez-Ibarluzea, Iñaki (Osasun Saila. Ezagutu Osteba arloa) ; Hviding, Krystyna (Norwegian Medicines Agency) ; Herholz, Harald (Kassenärztliche Vereinigung Hessen) ; Joppi, Roberta (Azienda Sanitaria Locale of Verona. Pharmaceutical Drug Department,) ; Kalaba, Marija (Republic Institute for Health. Department of Medicines and Pharmacoeconomics,) ; Laius, Ott (State Agency of Medicines) ; Malinowska, Kamila (National Health Fund. Drug Management Department,) ; Pedersen, Hanne B. (Division of Health Systems and Public Health, Health Technologies and Pharmaceuticals, WHO Regional Office for Europe) ; Markovic-Pekovic, Vanda (Ministry of Health and Social Welfare) ; Piessnegger, Jutta (Hauptverband der Österreichischen Sozialversicherungsträger) ; Selke, Gisbert (Wissenschaftliches Institut der AOK (WidO)) ; Sermet, Catherine (IRDES) ; Spillane, Susan (Trinity College. Department of Pharmacology and Therapeutics) ; Tomek, Dominik (Slovak Medical University. Faculty of Pharmacy) ; Vončina, Luka (Ministry of Health) ; Vlahović-Palčevski, Vera (University Hospital Rijeka. Unit for Clinical Pharmacology,) ; Wale, Janet (Independent Consumer Advocate, VIC) ; Wladysiuk, Magdalena (HTA Consulting) ; van Woerkom, Menno (Dutch Institute for Rational Use of Medicine) ; Zara, Corinne (Institut Català de la Salut) ; Gustafsson, Lars L. (Karolinska University Hospital Huddinge) ; Universitat Autònoma de Barcelona
Background : There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are effectiveness, safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. [...]
2014 - 10.3389/fphar.2014.00109
Frontiers in Pharmacology, Vol. 5 (june 2014)  
6.
13 p, 1.5 MB Biological Role of Aldo-Keto Reductases in Retinoic Acid Biosynthesis and Signaling / Ruiz, F. Xavier (University of Strasbourg. Institute of Genetics and of Molecular & Cellular Biology (IGBMC)- CNRS) ; Porte Orduna, Sergio (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ; Parés i Casasampera, Xavier (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ; Farrés i Vicén, Jaume (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Several aldo-keto reductase (AKR) enzymes from subfamilies 1B and 1C show retinaldehyde reductase activity, having low K and k values. Only AKR1B10 and 1B12, with all- trans -retinaldehyde, and AKR1C3, with 9- cis -retinaldehyde, display high catalytic efficiency. [...]
2012 - 10.3389/fphar.2012.00058
Frontiers in Pharmacology, Vol. 3 (April 2012) , art 58  
7.
10 p, 1.6 MB Etravirine pharmacokinetics in HIV-infected pregnant women / Mulligan, Nikki (University of California (Estats Units d'Amèrica)) ; Schalkwijk, Stein (Radboud University Nijmegen Medical Centre (Nijmegen, Països Baixos)) ; Best, Brookie M. (University of California (Estats Units d'Amèrica)) ; Colbers, Angela (Radboud University Nijmegen Medical Centre (Nijmegen, Països Baixos)) ; Wang, Jiajia (Harvard School of Public Health (Boston, Estats Units d'Amèrica)) ; Capparelli, Edmund V. (University of California (Estats Units d'Amèrica)) ; Moltó Marhuenda, José ((Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Stek, Alice M. (University of Southern California. School of Medicina (Estats Units d'Amèrica)) ; Taylor, Graham (Imperial College Healthcare National Health Service Trust (Londres, Regne Unit)) ; Smith, Elizabeth (National Institute of Allergy and Infectious Diseases (Bethesda, Estats Units d'Amèrica)) ; Hidalgo Tenorio, Carmen (Hospital Virgen de las Nieves (Granada, Andalusia)) ; Chakhtoura, Nahida (Eunice Kennedy Shriver National Institute of Child Health and Human Development (Bethesda, Estats Units d'Amèrica)) ; Van Kasteren, Marjo (Saint Elisabeth Hospital (Tilburg, Països Baixos)) ; Fletcher, Courtney V. (University of Nebraska Medical Center (Omaha, Estats Units d'Amèrica)) ; Mirochnick, Mark (Boston University School of Medicine (Estats Units d'Amèrica)) ; Burger, David (Radboud University Nijmegen Medical Centre (Nijmegen, Països Baixos)) ; PANNA Network ; IMPAACT Network
BACKGROUND: The study goal was to describe etravirine pharmacokinetics during pregnancy and postpartum in HIV-infected women. METHODS: IMPAACT P1026s and PANNA are on-going, non-randomized, open-label, parallel-group, multi-center phase-IV prospective studies in HIV-infected pregnant women. [...]
2016 - 10.3389/fphar.2016.00239
Frontiers in Pharmacology, Vol. 7 Núm. 239 (August 2016)  
8.
13 p, 1.5 MB Biological role of aldo-keto reductases in retinoic acid biosynthesis and signaling / Ruiz, F. Xavier (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Porte Orduna, Sergio (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Parés i Casasampera, Xavier (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ; Farrés i Vicén, Jaume (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Several aldo-keto reductase (AKR) enzymes from subfamilies 1B and 1C show retinaldehyde reductase activity, having low K m and kcat values. Only AKR1B10 and 1B12, with all-trans-retinaldehyde, and AKR1C3, with 9-cis-retinaldehyde, display high catalytic efficiency. [...]
2012
Frontiers in Pharmacology, Vol. 4 Núm. Article 58 (2012) , p. 1-13  
9.
13 p, 297.8 KB Individual differences and the characterization of animal models of psychopathology : a strong challenge and a good opportunity. / Armario García, Antonio (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Nadal i Alemany, Roser (Universitat Autònoma de Barcelona. Institut de Neurociències)
Despite the development of valuable new techniques (i. e. , genetics, neuroimage) for the study of the neurobiological substrate of psychiatric diseases, there are strong limitations in the information that can be gathered from human studies. [...]
2013 - 10.3389/fphar.2013.00137
Frontiers in Pharmacology, Vol. 4, Núm. 137 (November 2013) , p. 1-13  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.